BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

被引：0
作者：
Marcel Ebeling
Mario Scheurer
Andreas Sakkas
Sebastian Pietzka
Alexander Schramm
Frank Wilde
机构：
[1] Academic Hospital of the University of Ulm,Department of Oral and Plastic Maxillofacial Surgery, Military Hospital Ulm
[2] University Hospital Ulm,Department of Oral and Plastic Maxillofacial Surgery
来源：
Medical Oncology | / 40卷
关键词：
Ameloblastoma; BRAF; Facial reconstruction; Chemotherapy; Dabrafenib; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland
    Sollfrank, Lukas
    Lettmaier, Sebastian
    Erdmann, Michael
    Uslu, Ugur
    [J]. ANTICANCER RESEARCH, 2019, 39 (07) : 3955 - 3959
  • [42] Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
    Eriksen, Martina
    Hansen, Anne M.
    Nielsen, Annelaura B.
    Mundt, Filip
    Mann, Matthias
    Lassen, Ulrik
    Ahlborn, Lise B.
    Hojgaard, Martin
    Spanggaard, Iben
    Qvortrup, Camilla
    Yde, Christina W.
    Rohrberg, Kristoffer S.
    [J]. JCO PRECISION ONCOLOGY, 2025, 9
  • [43] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    [J]. ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [44] Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
    Burger, Michael C.
    Ronelenfitsch, Michael W.
    Lorenz, Nadja I.
    Wagner, Marlies
    Voss, Martin
    Capper, David
    Tzaridis, Theophilos
    Herlinger, Ulrich
    Steinbach, Joachim P.
    Stoffels, Gabriele
    Langen, Karl-Josef
    Brandts, Christian
    Senft, Christian
    Harter, Patrick N.
    Baehr, Oliver
    [J]. ONCOLOGY REPORTS, 2017, 38 (06) : 3291 - 3296
  • [45] Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
    Jafri, Sabih
    Yaqub, Abid
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [46] Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Bourque, Melissa S.
    Salek, Marta
    Sabin, Noah D.
    Canale, Meredith
    Upadhyaya, Santhosh A.
    [J]. PEDIATRIC BLOOD & CANCER, 2021, 68 (04)
  • [47] V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics
    Salimian, Kevan J.
    Fazeli, Roghayeh
    Zheng, Gang
    Ettinger, David
    Maleki, Zahra
    [J]. ACTA CYTOLOGICA, 2018, 62 (02) : 79 - 84
  • [48] Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma
    Parakh, S.
    Murphy, C.
    Lau, D.
    Cebon, J. S.
    Andrews, M. C.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (01) : 121 - 123
  • [49] Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
    Nelson, Blessie Elizabeth
    Reddy, Neha K.
    Huse, Jason T.
    Amini, Behrang
    Nardo, Mirella
    Gouda, Mohamed
    Weathers, Shiao-Pei
    Subbiah, Vivek
    [J]. NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [50] BRAF V600E mutation mediates invasive and growth features in ameloblastoma
    Zhang, Chen-Xi
    Zhang, Lin-Zhou
    Lin, Hao
    Man, Qi-Wen
    Liu, Bing
    [J]. ORAL DISEASES, 2024, 30 (07) : 4426 - 4439
12345